MitraClip works by clipping parts of the mitral valve together to mitigate the backflow of blood. Credit: Abbott.

The US Food and Drug Administration (FDA) has approved Abbott’s MitraClip G4 heart valve repair device for the treatment of patients with mitral regurgitation.

MitraClip G4 can be delivered to the heart via an incision in the leg. The device is intended to repair leaky mitral valves without the need for open-heart surgery.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It clips together the leaflet portions of the mitral valve in order to minimise the backflow of blood and restore the heart’s ability to pump oxygenated blood.

The latest fourth-generation device is said to feature new clip sizes and an improved leaflet grasping capability. It comes with independently controlled grippers to facilitate grasping of one or both leaflets.

Moreover, MitraClip G4’s upgraded catheter enables continuous monitoring of left atrial pressure in real time during the implant procedure. This is intended to help doctors decide positioning of the device for improved patient outcomes.

Abbott structural heart business chief medical officer Neil Moat said: “We are continually innovating the MitraClip technology based on the experience of the physicians implanting the device so we can truly help them improve the lives of their patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“With the fourth generation of MitraClip, we set out to build a system that would help physicians individualise the therapy to each patient and deliver even more features that can treat both primary and secondary mitral regurgitation.”

Abbott initially launched the MitraClip system in Europe in 2008 and in the US in 2013. To date, the device has been used to treat primary and secondary mitral regurgitation in more than 80,000 patients globally.

The FDA approved MitraClip for primary mitral regurgitation in 2013. The device secured regulator approval for secondary mitral regurgitation in March.